CLOU064J12301/2: Phase III studies in hidradenitis suppurativa

• Research type

  Research Study

• Full title

  A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa

• IRAS ID

  1009380

• Contact name

  Morgane Laurent

• Contact email

  morgane.laurent@novartis.com

• Sponsor organisation

  Novartis Pharma AG

• ISRCTN Number

  -

• Clinicaltrials.gov Identifier

  NCT06840392

• Research summary

  The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) 25 mg b.i.d. compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  25/NW/0141

• Date of REC Opinion

  30 Jun 2025

• REC opinion

  Further Information Favourable Opinion